人工智能用于肝细胞癌临床诊断及预后的研究进展

doi:10.3760/cma.j.cn441417-20250216-12010

摘要/Abstract

摘要：

肝细胞癌（hepatocellular carcinoma，HCC）是临床常见的消化系统恶性肿瘤，其早期诊断困难且预后较差。近年来，随着人工智能（artificial intelligence，AI）技术的飞速发展，其在改进HCC诊疗方面的价值也得到了体现。基于机器学习及深度学习的AI模型可以整合影像学、血清学及肠道菌群等多模态数据，从而提高HCC早期风险预测和病灶检测能力。此外，AI模型也能够通过特定的算法为介入治疗和药物治疗方案提供决策参考，并改进对HCC患者临床预后评估，从而使患者获得生存获益。虽然AI技术的发展极快，但是目前仍不能替代临床医生。随着如ChatGPT及Deepseek等划时代AI算法工具的出现，相信AI能够成为临床医生治疗HCC的强大武器，从而使更多患者从中获益。

关键词: 肝细胞癌, 人工智能, 机器学习, 深度学习, 诊断, 治疗, 预后, 进展

Abstract:

Hepatocellular carcinoma (HCC) is a common digestive system malignancy with challenging early diagnosis and poor prognosis. In recent years, the rapid development of artificial intelligence (AI) has demonstrated significant potential in improving HCC diagnosis and treatment. Machine learning (ML) and deep learning (DL)-based AI models can integrate multimodal data, including imaging, serological markers, and gut microbiota, thereby enhancing early risk prediction and lesion detection for HCC. Additionally, AI models provide decision support for interventional and pharmacological therapies through specific algorithms, while improving clinical prognosis assessment to optimize patient survival outcomes. Although AI cannot yet replace clinicians, the emergence of groundbreaking tools such as ChatGPT and DeepSeek suggests that AI will become a powerful adjunct in HCC management. This review summarizes recent advancements in AI-assisted HCC diagnosis, treatment decision-making, and prognosis evaluation, so as to provide insights for broader clinical applications of AI in HCC.

Key words: Hepatocellular carcinoma, , Artificial intelligence, , Machine learning, , Deep learning, , Diagnosis, , Treatment, , Prognosis, , Progress

朱鹏覃刚郭世民. 人工智能用于肝细胞癌临床诊断及预后的研究进展 [J]. 国际医药卫生导报, 2025, 31(12): 1979-1983.

Zhu Peng, Qin Gang, Guo Shimin.

Research progress on application of artificial intelligence in clinical diagnosis and prognosis of patients with hepatocellular carcinoma [J]. International Medicine and Health Guidance News, 2025, 31(12): 1979-1983.

参考文献

[1]Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.

[2]Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma [J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.

[3]Calderaro J, Seraphin TP, Luedde T, et al. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma [J]. J Hepatol, 2022, 76(6): 1348-1361. DOI: 10.1016/j.jhep.2022.01.014.

[4]Tangsrivimol JA, Darzidehkalani E, Virk HUH, et al. Benefits, limits, and risks of ChatGPT in medicine [J]. Front Artif Intell, 2025, 8: 1518049. DOI: 10.3389/frai.2025.1518049.

[5]Conroy G, Mallapaty S. How China created AI model DeepSeek and shocked the world [J]. Nature, 2025, 638(8050): 300-301. DOI: 10.1038/d41586-025-00259-0.

[6]Dimopoulos P, Mulita A, Antzoulas A, et al. The role of artificial intelligence and image processing in the diagnosis, treatment, and prognosis of liver cancer: a narrative-review [J]. Prz Gastroenterol, 2024, 19(3): 221-230. DOI: 10.5114/pg.2024.143147.

[7]Xiong M, Xu Y, Zhao Y, et al. Quantitative analysis of artificial intelligence on liver cancer: a bibliometric analysis [J]. Front Oncol, 2023, 13: 990306. DOI: 10.3389/fonc.2023.990306.

[8]Bakrania A, Joshi N, Zhao X, et al. Artificial intelligence in liver cancers: decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases [J]. Pharmacol Res, 2023, 189: 106706. DOI: 10.1016/j.phrs.2023.106706.

[9]Kim SS, Lee J, Ahn SB, et al. Clinical course and prognosis of long-term survivors of hepatocellular carcinoma [J]. Aliment Pharmacol Ther, 2025, 61(8): 1333-1342. DOI: 10.1111/apt.70004.

[10]Jin T, Luo M, Chen F, et al. Harnessing the power of AI for enhanced diagnosis and treatment of hepatocellular carcinoma [J]. Turk J Gastroenterol, 2024, 36(4): 200-208. DOI: 10.5152/tjg.2024.24325.

[11]Yang Y, Bo Z, Wang J, et al. Machine learning based on alcohol drinking-gut microbiota-liver axis in predicting the occurrence of early-stage hepatocellular carcinoma [J]. BMC Cancer, 2024, 24(1): 1468. DOI: 10.1186/s12885-024-13161-1.

[12]Shin H, Hur MH, Song BG, et al. AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B [J]. J Hepatol, 2024: S0168-8278(24)02784-3. DOI: 10.1016/j.jhep.2024.12.029.

[13]Salehi MA, Harandi H, Mohammadi S, et al. Diagnostic performance of artificial intelligence in detection of hepatocellular carcinoma: a meta-analysis [J]. J Imaging Inform Med, 2024, 37(4): 1297-1311. DOI: 10.1007/s10278-024-01058-1.

[14]Şahin E, Tatar OC, Ulutaş ME, et al. Diagnostic performance of deep learning applications in hepatocellular carcinoma detection using computed tomography imaging [J]. Turk J Gastroenterol, 2024, 36(2): 124-130. DOI: 10.5152/tjg.2024.24538.

[15]刘一萍,李新平,陈磊,等.基于人工智能的肝细胞癌精准影像学诊断和复发预测[J].临床肝胆病杂志,2022,38(3):521-527. DOI:10.3969/j.issn.1001-5256.2022.03.006.

[16]Lee IC, Tsai YP, Lin YC, et al. A hierarchical fusion strategy of deep learning networks for detection and segmentation of hepatocellular carcinoma from computed tomography images [J]. Cancer Imaging, 2024, 24(1): 43. DOI: 10.1186/s40644-024-00686-8.

[17]Laohawetwanit T, Apornvirat S, Namboonlue C. Thinking like a pathologist: Morphologic approach to hepatobiliary tumors by ChatGPT [J]. Am J Clin Pathol, 2025, 163(1): 3-11. DOI: 10.1093/ajcp/aqae087.

[18]Takamoto T, Mihara Y, Nishioka Y, et al. Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies [J]. Int J Clin Oncol, 2025, 30(3): 417-426. DOI: 10.1007/s10147-025-02703-7.

[19]Zheng J, Wang S, Xia L, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances [J]. Signal Transduct Target Ther, 2025, 10(1): 35. DOI: 10.1038/s41392-024-02075-w.

[20]Quan B, Li J, Mi H, et al. Development and preliminary validation of a novel convolutional neural network model for predicting treatment response in patients with unresectable hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy [J]. J Imaging Inform Med, 2024, 37(4): 1282-1296. DOI: 10.1007/s10278-024-01003-2.

[21]An C, Wei R, Liu W, et al. Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: a national real-world evidence-based study [J]. Br J Cancer, 2024, 131(5): 832-842. DOI: 10.1038/s41416-024-02784-7.

[22]Eghbali S, Heumann TR. Next-generation immunotherapy for hepatocellular carcinoma: mechanisms of resistance and novel treatment approaches [J]. Cancers (Basel), 2025, 17(2): 236. DOI: 10.3390/cancers17020236.

[23]Zeng Q, Klein C, Caruso S, et al. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study [J]. Lancet Oncol, 2023, 24(12): 1411-1422. DOI: 10.1016/S1470-2045(23)00468-0.

[24]Nakao Y, Nishihara T, Sasaki R, et al. Investigation of deep learning model for predicting immune checkpoint inhibitor treatment efficacy on contrast-enhanced computed tomography images of hepatocellular carcinoma [J]. Sci Rep, 2024, 14(1): 6576. DOI: 10.1038/s41598-024-57078-y.

[25]European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma [J]. J Hepatol, 2025, 82(2): 315-374. DOI: 10.1016/j.jhep.2024.08.028.

[26]Romeo M, Dallio M, Napolitano C, et al. Clinical applications of artificial intelligence (AI) in human cancer: is it time to update the diagnostic and predictive models in managing hepatocellular carcinoma (HCC)? [J]. Diagnostics (Basel), 2025, 15(3): 252. DOI: 10.3390/diagnostics15030252.

[27]Wang S, Shao M, Fu Y, et al. Deep learning models for predicting the survival of patients with hepatocellular carcinoma based on a surveillance, epidemiology, and end results (SEER) database analysis [J]. Sci Rep, 2024, 14(1): 13232. DOI: 10.1038/s41598-024-63531-9.

[28]Zhang Y, Shi K, Feng Y, et al. Machine learning model using immune indicators to predict outcomes in early liver cancer [J]. World J Gastroenterol, 2025, 31(5):101722. DOI: 10.3748/wjg.v31.i5.101722.

[29]Xia F, Chen Q, Liu Z, et al. Machine learning models for predicting postoperative peritoneal metastasis after hepatocellular carcinoma rupture: a multicenter cohort study in China [J]. Oncologist, 2025, 30(1): oyae341. DOI: 10.1093/oncolo/oyae341.

[30]Wu L, Lai Q, Li S, et al. Artificial intelligence in predicting recurrence after first-line treatment of liver cancer: a systematic review and meta-analysis [J]. BMC Med Imaging, 2024, 24(1): 263. DOI: 10.1186/s12880-024-01440-z.